Abstract
Introduction
MCI is a borderline condition between normal aging and dementia affecting
around 23.4 million subjects across the seven major markets (US, Japan,
France, Germany, Italy, Spain and the UK) in 2007, 37% of whom were suffering
from prodromal Alzheimer' s disease. MCI-specific annual sales are expected to
increase seven-fold from 2007 to $3.3 billion across the seven major markets
by 2018.
Scope of this research
- Definition and prevalence of MCI and its major sub-types.
- Review of the key unmet needs in the treatment of the MCI subtypes as
identified by key opinion leaders.
- MCI-specific drug sales value and number of treated patients forecasts to
2018 in the US, Japan, and five major European markets.
- Pipeline analysis with detailed profiles for key late-stage drugs
potentially appropriate for MCI patients.
Research and analysis highlights
Driven by off-label sales of several products currently in development for
Alzheimer' s disease, MCI-specific annual sales are expected to increase
seven-fold from 2007 to $3.3 billion across the seven major markets by 2018.
Although Datamonitor anticipates growth in the number of treated MCI patients
(2.3% in 2007 rising to 4.27% in 2018), the treatment rate will remain
hampered by the slow uptake of relatively expensive diagnostic tools and lack
of marketing authorization for drugs within the forecast period.
In the long-term, Datamonitor believes that MCI will become a viable
indication expansion opportunity for companies marketing dementia drugs.
However, the current marketed drugs for Alzheimer' s disease are not
appropriate, and new drugs for dementia are still a few years from the market.
Key reasons to purchase this research
- Better understand the concept of MCI and its limits in the identification
of the syndromes sub-types and the approval of treatments.
- Quantify the MCI-specific market to 2018 in the US, Japan, and five major
European markets and identify the drivers and resistors in this market.
- Understand unmet needs and opportunities in the definition, diagnosis and
management of MCI based on key opinion leader comments.
| 
View Cart
